We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Technopath Clinical Diagnostics

Technopath Clinical Diagnostics develops and manufactures total quality control (QC) solutions for clinical laborator... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
22 May 2021 - 26 May 2021
Virtual Venue
25 May 2021 - 28 May 2021

LGC Acquires Technopath Clinical Diagnostics to Strengthen Position in Clinical Diagnostics QC Market

By LabMedica International staff writers
Posted on 03 Feb 2021
Print article
LGC (Middlesex, UK) has acquired Technopath Clinical Diagnostics (Tipperary, Ireland), a developer and manufacturer of quality control (QC) solutions for clinical laboratories.

Technopath Clinical Diagnostics’ QC and software products are used by laboratories in over 120 countries globally. The acquisition augments LGC’s position in the clinical diagnostics QC market, complementing a wide breadth of existing manufacturing capabilities across calibration verification materials, molecular diagnostics and serology controls, clinical genomics reference materials and viral antigens.

“We are really excited to be bringing Technopath’s full-fledged chemistry and immunoassay controls into LGC,” said Euan O’Sullivan, President & Chief Operating Officer, LGC. “Their multi-constituent quality control products will dovetail perfectly with the calibration verification, molecular and serology product portfolios within our Clinical Diagnostics business unit. We look forward to combining Technopath’s and LGC’s expertise to deliver unrivalled solutions for our customers.”

“We are delighted to be joining LGC as an integral part of their fast-growing Clinical Diagnostics unit,” added Malcolm Bell, Chief Executive Officer, Technopath Clinical Diagnostics. “Technopath and LGC are an excellent fit as we share a purpose and mission, to support our customers by providing an expanded breadth of capability, geographic reach and scale. Our test consolidated multi analyte QC products allow end-customer labs to optimise their entire QC testing strategy while reducing waste and storage requirements and most importantly, reporting patient results with enhanced confidence and greater accuracy.”

Related Links:
Technopath Clinical Diagnostics

Gold Supplier
Streptococcus Test
COVID-19 IgG/IgM Test
Accu-Tell COVID-19 IgG/IgM
SARS-CoV-2 Antigen Test
NG Test SARS-CoV-2 Ag
Pipette Manager
VisioNize Pipette Manager

Print article
Mayo Medical Laboratories
BIOHIT  Healthcare OY


Molecular Diagnostics

view channel
Image: Photograph of the novel capsule-based smell test (Photo courtesy of Queen Mary University of London)

A Novel Capsule-Based Smell Test for Diagnosis of Neurological and Respiratory Diseases

To aid in diagnosing diseases where loss of the sense of smell is a symptom, such as in chronic neurological conditions like Parkinson's and Alzheimer's diseases and in acute respiratory infections such... Read more


view channel
Image: The Hamamatsu Photonics Nanozoomer 1 Digital Slide Scanner (Photo courtesy of University of Adelaide)

Genetic Background and Clinicopathologic Features Established for Adult-Onset Nephronophthisis

Nephronophthisis (NPH) is a genetic disorder of the kidneys which mainly affects children. It is classified as a medullary cystic kidney disease. The disorder is inherited in an autosomal recessive fashion... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.